The United Kingdom’s medicines regulator has approved the initiation of human testing for an experimental Ebola vaccine, marking the first of four candidate vaccines in development to advance to clinical trials. Researchers at the University of Oxford began developing the vaccine eight weeks ago in response to a public health emergency declaration, with recruitment of volunteers now underway and initial doses to be administered to healthy adults “within weeks.”
The current Ebola outbreak, centered in the Democratic Republic of the Congo, has resulted in 625 deaths among 1,792 laboratory-confirmed cases. The outbreak is caused by the Bundibugyo species of Ebola, a variant that has produced two previous outbreaks and for which no approved treatments or vaccines currently exist. The ongoing nature of the outbreak, combined with its location in a conflict zone characterized by highly mobile populations, has intensified the urgency for vaccine development.
The Oxford team leveraged technology developed during the COVID-19 pandemic to accelerate the vaccine’s creation. The approach utilizes a genetically modified chimpanzee cold virus as a delivery vehicle, into which researchers inserted genetic code from the Bundibugyo species of Ebola. The vaccine does not cause infection but prompts the body to produce a single viral protein from Ebola, triggering an immune response. The Serum Institute of India has already manufactured and stockpiled approximately 620,000 doses.
The trial will involve 50 healthy adults aged 18 to 55, with participants monitored for one year to assess immune response and identify any unexpected adverse effects. Researchers are simultaneously preparing for trials in Africa in partnership with Ugandan institutions. While vaccine development typically requires a decade, researchers emphasize that standard safety testing protocols are being maintained through parallel processing rather than by eliminating any procedural steps. Three additional vaccine candidates are under development by other organizations, including approaches using mRNA technology and techniques previously proven effective against other Ebola species variants.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI